Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

11/23/2012

Form 4

November 26, 2012

								OMB AF	PPROVAL	
FURI	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Expires: January 37 200 Estimated average burden hours per										
(Print or Type	Responses)									
Terifay Robert J Sym REG PHA			2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [REGN]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last)	(First) (M	(Month/	3. Date of Earliest Transaction X Officer (below)			X_ Officer (give below)				
ROAD		11/21/	2012							
TARRYTO	mendment, Date Original Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State) ((Zip) Tal	ble I - Non-	Derivative	Secur	ities Acqu	ired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	, ,	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired (A Transactiom Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or				Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common			Code V		(D)	Price	(Instr. 3 and 4)			
Stock	11/21/2012		M	20,000	A	\$ 16.8	29,372	D		
Common Stock	11/21/2012		F	1,932	D	\$ 173.83	27,440	D		
Common Stock	11/21/2012		F	8,323	D	\$ 173.83	19,117	D		
Common Stock	11/23/2012		S	1,000	D	\$ 173.9 (1)	18,117	D		

6,700

D

11,417

D

S

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

\$ Common Stock 174.33 (2) \$ Common 11/23/2012 S 2,045 D 175.09 9,372 D Stock (3) Common By 401(k) 1,531 Ι Stock Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of **SEC 1474** information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and Ar Underlying Se (Instr. 3 and 4)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title 1
Non-Qualified Stock Option (right to buy)	\$ 16.8	11/21/2012		M	20,000	12/31/2011(4)	12/17/2018	Common Stock

Reporting Owners

Reporting Owner Name / Address	Relationships					
. 0	Director	10% Owner	Officer	Other		
Terifay Robert J						
777 OLD SAW MILL RIVER ROAD			SVP Commercial			
TARRYTOWN, NY 10591						

Signatures

/s/**Robert J.	
Terifay	11/26/2012
**Signature of Reporting Person	Date

2 Reporting Owners

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents volume-weighted average price of sales of 1,000 shares of Company stock on November 23, 2012 at prices ranging from (1) \$173.90 to \$173.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2012 at each separate price.
- Represents volume-weighted average price of sales of 6,700 shares of Company stock on November 23, 2012 at prices ranging from (2) \$174.00 to \$174.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2012 at each separate price.
- Represents volume-weighted average price of sales of 2,045 shares of Company stock on November 23, 2012 at prices ranging from \$175.00 to \$175.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 23, 2012 at each separate price.
- (4) The option became exercisable with respect to all shares underlying the option on December 31, 2011, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2011.
- (5) Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.